Scarica l'app Stockscreener
0.7188
5.32%
0.0363
Dopo l'orario di chiusura:
.71
-0.0088
-1.22%
Precedente Chiudi:
$0.6825
Aprire:
$0.7
Volume 24 ore:
252.41K
Relative Volume:
2.80
Capitalizzazione di mercato:
$6.74M
Reddito:
$34.07M
Utile/perdita netta:
$-20.13M
Rapporto P/E:
-0.0556
EPS:
-12.92
Flusso di cassa netto:
$-24.90M
1 W Prestazione:
+0.81%
1M Prestazione:
-14.43%
6M Prestazione:
-13.72%
1 anno Prestazione:
-38.56%
Intervallo 1D:
$0.67
$0.741
Intervallo di 1 settimana:
$0.67
$0.741
Portata 52W:
$0.6513
$2.22
Biofrontera Inc Stock (BFRI) Company Profile
Nome
Biofrontera Inc
Settore
Telefono
781-245-1325
Indirizzo
120 PRESIDENTIAL WAY,, WOBURN
Confronta BFRI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BFRI
Biofrontera Inc
|
0.7188 | 6.74M | 34.07M | -20.13M | -24.90M | -12.92 |
|
ZTS
Zoetis Inc
|
160.41 | 66.72B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.45 | 48.08B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 47.74B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.48 | 18.49B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
308.07 | 13.31B | 2.76B | 1.11B | 898.10M | 22.77 |
Biofrontera Inc Borsa (BFRI) Ultime notizie
Biofrontera (BFRI) to Release Earnings on Thursday - Defense World
Dermatology Leader Biofrontera Announces First Quarter 2025 Earnings Date: Key Details Inside - Stock Titan
Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025 - ACCESS Newswire
Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis - GlobeNewswire
Major Skin Cancer Prevention Campaign Launches as 58M Americans Face Actinic Keratosis Risk - Stock Titan
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update - ADVFN
Press Release Distribution & PR Platform - ACCESS Newswire
Biofrontera Inc. (NASDAQ:BFRI) Sees Large Decrease in Short Interest - Defense World
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - Revista ADVFN
Biofrontera Inc. Reports Record Sales and Strategic Advances - MSN
Virtu Financial LLC Invests $48,000 in Biofrontera Inc. (NASDAQ:BFRI) - The AM Reporter
Benchmark maintains Buy rating on Biofrontera stock, target at $7 By Investing.com - Investing.com Australia
Biofrontera Inc. (NASDAQ:BFRI) Q4 2024 Earnings Call Transcript - MSN
Benchmark maintains Buy rating on Biofrontera stock, target at $7 - Investing.com India
Biofrontera outlines 2025 growth strategies with new FDA approvals and clinical progress - MSN
Biofrontera Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Biofrontera Inc (BFRI) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amidst Financial ... By GuruFocus - Investing.com Canada
Biofrontera Inc. Q4 2024 Earnings: A Deep Dive into the Numbers - AInvest
Biofrontera Inc. Reports Record Revenue Growth in 2024 - TipRanks
Biofrontera Inc. reports Q4 EPS (19c) vs $1.65 last year - TipRanks
Earnings call transcript: Biofrontera Q4 2024 sees revenue growth and strategic shifts - Investing.com India
Biofrontera Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update - TradingView
Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update - GlobeNewswire Inc.
Earnings Scheduled For March 21, 2025 - Benzinga
Biofrontera Inc. (BFRI) reports earnings - Quartz
Biofrontera Inc. SEC 10-K Report - TradingView
Biofrontera Completes Patient Enrollment for Phase 3 Trial of Ameluz in Actinic Keratoses - Marketscreener.com
Biofrontera completes patient enrollment in Phase 3 study of Ameluz - TipRanks
Biofrontera Inc. Announces Completion of Patient Enrollment - GlobeNewswire
Major Milestone: Biofrontera's Skin Cancer Treatment Targets New Body Areas in Phase 3 Trial - StockTitan
3 Reasons to Avoid KIND and 1 Stock to Buy Instead - The Globe and Mail
Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk - GlobeNewswire
Biofrontera (BFRI) to Release Earnings on Friday - Defense World
Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025 - GlobeNewswire
BIOFRONTERA Earnings Preview: Recent $BFRI Insider Trading, Hedge Fund Activity, and More - Nasdaq
Dermatology Leader Biofrontera Sets Q4 Earnings Date: Key Growth Updates Expected - StockTitan
Biofrontera (BFRI) Projected to Post Earnings on Thursday - Defense World
Biofrontera Inc. (NASDAQ:BFRI) Short Interest Down 25.0% in February - Defense World
Investors Aren't Entirely Convinced By Biofrontera Inc.'s (NASDAQ:BFRI) Revenues - Simply Wall St
When Will Biofrontera Inc. (NASDAQ:BFRI) Turn A Profit? - Yahoo Finance
Biofrontera (NASDAQ:BFRI) Trading Down 3.5% – What’s Next? - Defense World
Constellation Brands: A Fallen Star or a Hidden Value Play? - The Globe and Mail
Biofrontera Inc Azioni (BFRI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):